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Increased expression of thioredoxin (Trx)-1 and matrix metalloproteinase (MMP)-9 associates with
malignant breast cancer progression. Here, we describe a functional relationship between Trx-1 and
MMP-9 in promoting MDA-MB-231 breast cancer cell invasive behaviour. Trx-1 overexpression stim-
ulated MMP-9 expression, de-regulated the MMP-9/TIMP-1 equilibrium and augmented MMP-9
involvement in a more invasive phenotype. Trx-1 augmented MMP-9 transcription through NF-
jB, AP-1 and SP1 elements; stimulated p50/p65 NF-jB activity and recruitment to the MMP-9 pro-
moter; and facilitated MMP-9 promoter-accessibility to NF-jB by preventing HDAC recruitment
and maintaining MMP-9 promoter histone acetylation. Our data provide a functional basis for
Trx-1 and MMP-9 association in malignant breast cancer and identify Trx-1 and NF-jB as potentially
druggable targets for reducing MMP-9 involvement in malignant behaviour.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction expressed in breast cancer and promotes aggressive behaviour inMetastatic malignant breast cancer progression is a complex
process involving metastasis-associated genes thioredoxin (Trx)-1
and matrix metalloproteinase (MMP)-9 [1–15].
Trx-1 is a 12 kDa multifunctional redox protein, which together
with Trx reductase and NADPH, comprises a powerful protein cys-
teine disulphide oxi-reductase system [6]. Trx-1 redox activity re-
sides within a Cys32-Gly-Pro-Cys35 catalytic active site, which
undergoes reversible oxidation–reduction [1,4,16]. Trx-1 is overchemical Societies. Published by E
metalloproteinase-9; TIMP,
deacetylase; NF-jB, nuclear
e
erimental Pathology, Depart-
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R. Mackay).
ork.breast cancer models [1–6]; stimulates tumour cell proliferation
whilst protecting against oxidative stress and apoptosis [16]; inac-
tivates PTEN oncosuppressor [17]; promotes and deregulates angi-
ogenesis [6,18]; promotes extracellular proteolysis by inhibiting
TIMP function [19]; and regulates NIF, AP-1, NFjB and SP1 tran-
scription factor activity [20–22]. Trx promotion of malignant
breast cancer can be reversed by dominant negative (dn) C32S/
C35S mutated Trx [3,4,16].
MMP-9 is involved in induction and maintenance of the malig-
nant phenotype [7,12–15,23–25]; triggers tumour-associated angi-
ogenesis [10,26], promotes tumour cell invasion [12,14,15,27,28],
down-regulates tumour-associated immunological surveillance
[29] and prepares organ parenchyma for metastatic tumour
growth [30]. MMP-9 expression is regulated at transcriptional
and post-transcriptional levels [31–33]. Basal and induced MMP-
9 transcription depends upon AP-1, Ets, SP1, GTbox and NFjB
elements within the MMP-9 promoter and cognate transcriptionlsevier B.V. All rights reserved.
A.R. Farina et al. / FEBS Letters 585 (2011) 3328–3336 3329factors [27,28,32,34–36]; is regulated by promoter-associated his-
tone acetylation and repressed by histone deacetylases (HDACs)
recruited by transcriptional repressors, including metastasis asso-
ciated gene-1 (Mta-1) [37]. Changes in mRNA stability regulate
MMP-9 expression at the post transcriptional level [33].
In this study, we unveil a novel functional interaction between
Trx-1 and MMP-9 in a MDA-MB-231 cell model of malignant p53
and ER-independent breast cancer. We report that Trx-1 stimulates
MMP-9 expression, de-regulates the equilibrium between MMP-9
and its speciﬁc inhibitor TIMP-1 and increases MMP-9 involvement
in a more invasive phenotype, we characterise a critical role for the
transcription factor NF-jB in this effect and identify Trx-1 and NF-
jB as druggable therapeutic targets to reduce MMP-9 involvement
in breast cancer.
2. Materials and methods
2.1. Cells and reagents
MDA-MB-231 breast cancer cells and human MMP-9 and TIMP-
1 antibodies, have been described previously [27,28]. Anti-catalytic
MMP-9 antibody and recombinant human TIMP-1 were from
Oncogene Science (Cambridge MA); p65, p50, HDAC-1, HDAC-2
and Mta-1 antibodies were Santa Cruz Biotechnology (Santa Cruz,
CA); the acetylated Histone 3 antibody was from Upstate Biotech-
nology (Lake Placid, NY). The anti-Trx-1 antibody was from IMCO
(Stockholm Sw). Dominant negative mutant I-jBa inhibitor of
NF-jB in pmT2T vector was provided by Dr. U. Siebenlist (NIH,
Bethesda, MD) [40]. Trx-1 pcDNA3.1 and C32S/C35S-mutated
Trx-1 pcDNA3.1 (dn-Trx-1) vectors were obtained by sub-cloning
previously characterised full length human Trx-1 and C32S/C35S
mutated Trx-1 cDNAs [39] into mammalian expression vector
pcDNA3.1 (Invitrogen). MDA-MB-231 cells stable transfected with
pcDNA 3.1, using Lipofectamine™ as directed (Invitrogen), were
isolated by 100 lg/ml Zeocin resistance.
2.2. Zymograms and Western blots
Gelatin zymograms and Western blots were performed as pre-
viously described [27,40].
2.3. Invasion assays
Invasion through reconstituted Matrigel (Collaborative Re-
search, Bedford, MA) was performed as previously described [12],
with inhibitors added directly to invasion medium at the concen-
trations stipulated.
2.4. Nuclear extracts and EMSAs
Nuclear extracts were prepared, and regular and supershift EM-
SAs performed, as previously described [27]. For EMSAs, the fol-
lowing oligonucleotides were used:
 MMP-9 AP-1 (50-CCTGACCCCTGAGTCAGCACTTGCCTGT-30);
 MMP-9 NF-jB (50-TGCCCCAGTGGAATTCCCCAGCCTTG-30) and
 MMP-9 Sp1 (50-GTGCCTTCCGCCCCCAGATGAA-30).
All oligonucleotides were double stranded, complementary afﬁnity
strands are not indicated.
2.5. RT-PCR
Total RNAs (1 lg) were reverse transcribed using Moloney Mur-
ine Leukaemia virus reverse transcriptase kit (Life Technologies
Inc., Paisley, UK), as directed. RT reactions were subjected to PCRampliﬁcation using primers sets for: Trx-1: 50-GAATTCGCTTTGG
ATCCATTTCCATCG-30 and 50-CAAGTTTAAATAGCCAATGGCTGGT-
TA-30; MMP-9 50-TGGACGATGCCTGCAACGTG-30 and 50-GTCGTGC
GTGTCCAAAGGCA-30; TIMP-1 50-AGCGCCCAGAGAGACACCAG-30
and 50-CCACTGCGGGCAGGATTCAG-30 and GAPDH 50-CGGAGT
CAACGGATTTGGTCGTAT-30 and 50-AGCCTTCTCCATGGTGG TGAA-
GAC-30. RT-PCR products were resolved by 1.5% agarose gel
electrophoresis.
2.6. Luciferase reporter gene and b-galactosidase assays plasmids
Luciferase reporter gene constructs -670MMP-9-Luc, -
670AP1mu-Luc (mutation of the proximal -79 AP-1 site from
TGAGTCA to gtcacCg), -670GTmu-Luc (mutation of the -54 GT box
from GGGGTGGGG to GGGtTaacG), -670SP1mu-Luc (mutation of
the -560 SP1 site from CCGCCCC to CgtCaaC) and -670NFjBmu-Luc
(mutation of the -600 NFjB element from GGAATTCCCC to
GGcAaccCgg) were prepared by sub-cloning previously char-
acterised -670MMP-9; -670AP1mu; -670GTmu; -670SP1mu;
-670NFjBmu and MMP-9 NF-kB sequences of -670MMP-9CAT;
-670AP1mu-CAT; -670GTmuCAT, -670SP1muCAT, -670NFjBmu-
CAT and D56NFkBCAT reporter gene constructs [27] into the PGL3
luciferase reporter plasmid (Promega Madison WI). Luciferase re-
porter genes were sequence veriﬁed and the mutations introduced
into relevant binding sites veriﬁed as inhibiting speciﬁc binding by
EMSA. Luciferase reportergeneandb-galactosidaseassayswereper-
formed following 48 h transient transfection with luciferase and
pRSVbgal reporter genes (Invitrogen), as previously described
[41,42].
2.7. Chromatin immunoprecipitation
ChIp assays were performed as previously described [43].
Immunoprecipitated chromatin was subjected to PCR ampliﬁca-
tion using 100 ng/ll of each unlabeled oligonucleotide primer de-
signed to amplify the region spanning -634 to -484 of the MMP-9
promoter (50-ATTCAGCCTGCGGAAGACCAG-30 and 50-ACT-
CCAGGCTCTGTCCTC TT-3, respectively) in a reaction containing
500 lM dNTPs, 67 mM Tris–HCl; 6.7 mM MgCl2; 170 lg/ml BSA;
16.6 mM (NH4)2SO4) and one unit of Taq Polymerase (35 cycles
of 95 C for 30 s; 56 C for 30 s and 72 C for 30 s). Products were
separated by 10% non-denaturing acrylamide gel electrophoresis.
2.8. Statistical analysis
Differences between means were evaluated by Student’s t-test,
with t-value-associated probabilities of 60.05 considered statisti-
cally signiﬁcantly.
3. Results
3.1. Stable transfectants
Densitometric analysis of Western blots indicated that constitu-
tive Trx protein expression in stable MDA-MB-231 pcDNA control
transfectants (a and b) was moderately increased with respect to
b-actin levels in both stable Trx-1 (a and b) and dnTrx-1 (a and
b) transfectants (Fig. 1A). The presence of Trx-1 and dn-Trx1
expression vectors in stable transfectants was conﬁrmed by PRC
using Trx and pcDNA-speciﬁc primers (Fig. 1A, bottom panel).3.2. Trx-1 stimulates MMP-9 expression
Differences in MMP-9 activity, MMP-9 and TIMP-1 expression
were assessed by zymogram, Western blot and RT-PCR using equal
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Fig. 1. (A) Western blots demonstrating Trx-1 and b-actin expression in stable pcDNA control, Trx-1 and dnTrx-1 transfectants, plus PCR presence of Trx/dnTrx-1 expression
vector in Trx-1 and dnTrx-1 but not in pcDNA stable transfectants. The adjacent histogram shows the percent difference in Trx-1/b-actin ratio assessed by densitometry of the
adjacent Western blots, using pcDNA (cl.a) (100%) as the baseline. (B) Gelatin zymogram (zym) and Western blots comparing MMP-9 activity and expression and TIMP-1
expression in equal numbers of pcDNA control, Trx-1 and dnTrx-1 transfectants. The adjacent histograms depict the percent differences in TIMP-1 levels and MMP-9/TIMP-1
ratios assessed by densitometry of the adjacent Westerns, using pcDNA (cl. A) as the baseline. (C) Agarose gels demonstrating RT-PCR levels of MMP-9, TIMP-1 and GAPDH
mRNAs in control pcDNA, Trx-1 and dnTrx-1 transfectants. The histograms beneath show the percent densitometric differences in TIMP-1/GAPDH; MMP-9/GAPDH and MMP-
9/TIMP-1 ratios with respect to pcDNA transfectant clone a (100%), in the gels above. (D) Western blots demonstrating MMP-9 and TIMP-1 protein levels in concentrated 48-h
serum-free conditioned medium from untreated stable Trx-1 transfectants (con) and stable Trx-1 transfectants transiently transfected with either empty pcDNA expression
vector (pcDNA) or dnTrx-1 expression vector (dn-Trx-1). The adjacent histogram shows the percent difference in MMP-9 and TIMP-1 expression assessed by densitometry of
the adjacent Westerns, using untreated stable Trx-1 transfectant controls (100%) as the baseline.
3330 A.R. Farina et al. / FEBS Letters 585 (2011) 3328–3336numbers of pcDNA control, Trx-1 and dnTrx-1 transfectants. Den-
sitometric analysis of zymograms, Western blots (Fig. 1B) and
RT-PCR reactions (Fig. 1C) revealed that MMP-9 activity, mRNAand protein expression in pcDNA controls was more than doubled
in Trx-1 stable transfectants relative to TIMP-1 expression. In con-
trast, MMP-9 but not TIMP-1 protein (Fig. 1B) and mRNA (Fig. 1C)
A.R. Farina et al. / FEBS Letters 585 (2011) 3328–3336 3331expression in dnTrx-1 transfectants (a and b) was abrogated, with
MMP-9/TIMP-1 protein (Fig. 1B) and mRNA (Fig. 1C) ratios altered
in favour of MMP-9 in Trx-1 transfectants and in favour of TIMP-1
in dn-Trx transfectants. Transient dn-Trx-1 transfection into stable
Trx-1 transfectants reduced MMP-9 protein expression without
affecting that of TIMP-1, compared to transient pmT2T-transfected
counterparts (Fig. 1D).
3.3. Trx-1 augments MMP-9 involvement in MDA-MB-231 invasion
Trx-1 MDA-MB-231 transfectants exhibited a signiﬁcant
75 ± 2.9% (±S.E.) increase (P 6 0.05, n = 24) (Fig. 2) and dnTrx-1
transfectants a signiﬁcant 55 ± 3.1% decrease (P 6 0.05, n = 24) in
invasion, when compared to pcDNA transfectants (Fig. 2). Recom-
binant human TIMP-1 (10 lg/ml) and anti-catalytic anti-MMP-9
antibody (100 lg/ml) signiﬁcantly inhibited pcDNA transfectant
invasion by 35 ± 3.5% (P 6 0.05, n = 12) and 35 ± 4.8% (P 6 0.05,
n = 12), respectively, and inhibited Trx-1 transfectant invasion by
51.5 ± 3.6% (P 6 0.05, n = 12) and 45.8 ± 4.2% (P 6 0.05, n = 12),
respectively, when compared to untreated controls (Fig. 2). Recom-
binant human TIMP-1 (10 lg/ml) and anti-catalytic anti-MMP-9
antibody (100 lg/ml) did not reduce dnTrx-1 transfectant invasion
(Fig. 2). Transient 48 h dn-Trx-1 transfection prior to invasion as-
say signiﬁcantly inhibited pcDNA transfectant invasion by
33.8 ± 6.2% (P < 0.05 n = 6), inhibited Trx-1 transfectant invasion
by 47.2 ± 5.8% (P < 0.05, n = 6), (Fig. 2) but did not reduce dn-Trx-
1 transfectant invasion, when compared to pmT2T transiently-
transfected controls (Fig. 2).
3.4. Trx-1 stimulates MMP-9 transcription
MMP-9 mRNA stability over 10 h, in the presence of actinomy-
cin D (5 lg/ml) was not augmented in Trx-1 compared to pcDNA
transfectants. MMP-9 but not TIMP-1 or GAPDH mRNA was lost
by 10 h in both cell lines (Fig. 3A).
MMP-9 luciferase reporter gene assays revealed signiﬁcant dif-
ferences in transcription between pcDNA and Trx-1 MDA-MB-231
transfectants. Basal transcription in pcDNA transfectants (arbitrary
value, 100%) was signiﬁcantly augmented in Trx-1 transfectants by
65 ± 4.8% (±S.E.) (P < 0.05, n = 12) (Fig. 3B). GT box mutation
(-670GTmu) did not reduce transcription in pcDNA or Trx-1 trans-
fectants, Sp1 mutation (-670SPmu) signiﬁcantly reduced transcrip-
tion in pcDNA and Trx-1 transfectants by approximately 30%0
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Fig. 2. Histogram depicting Matrigel invasion by stable pcDNA, Trx-1 and dn-Trx-1
transfectants in invasion medium (1) alone; (2) plus 1 lg/ml of exogenous
recombinant human TIMP-1; (3) plus 100 lg/ml of anti-catalytic anti-MMP-9
antibody; (4) following transient transfection with dnTrx-1 vector, and (5)
following transient transfection with 10 lg pmT2T vector. Results are displayed
as percent change in mean invasion (±S.E.), compared to invasion of pcDNA controls
in the presence of 100 lg/ml of pre-immune IgG (100%).(P < 0.05, n6, for both pcDNA and Trx-1 transfectants); AP-1 muta-
tion (-670AP-1mu) signiﬁcantly reduced transcription in pcDNA
and Trx-1 transfectants by approximately 60% (P < 0.05, n6, for
both pcDNA and Trx-1 transfectants) and NF-jB mutation (-670
NF-jBmu) signiﬁcantly reduced transcription by approximately
80% a in both pcDNA and Trx-1 transfectants (P < 0.05, n = 6, for
both pcDNA and Trx-1 transfectants) (Fig. 3B). Transcription in
dn-Trx transfectants was signiﬁcantly attenuated by 46 ± 4.5%
(P < 0.05, n = 12) compared to pcDNA controls and was signiﬁ-
cantly reduced further in AP-1 mutated (-670AP-1mu) and NF-jB
mutated (-670NF-jBmu) but not -670GTmu or -670SP1mu con-
structs (Fig. 3B), indicating that abrogation of MMP-9 expression
in dn-Trx transfectants is not accompanied by abrogation of tran-
scription from the MMP-9 reporter gene.
In NF-jB luciferase reporter gene assays constitutive NF-jB
activity in pcDNA transfectants was signiﬁcantly augmented by
92 ± 7.4% (P < 0.05, n = 12) in Trx-1 transfectants and signiﬁcantly
reduced by 32 ± 4.3% (P < 0.05, n = 12) in dnTrx-1 transfectants
(Fig. 3C). Transient transfection with the mutated dominant nega-
tive (dn) I-jBa inhibitor of NF-jB [40] signiﬁcantly reduced MMP-
9 luciferase reporter gene activity by 49.8 ± 10.3%, (P < 0.05, n = 9)
in Trx-1 transfectants and by 35 ± 8.5% (P < 0.05, n = 9) in pcDNA
transfectants, when compared to pmT2T vector transfected con-
trols (Fig. 3D). Transient 48 h dn I-jBa transfection inhibited
MMP-9 but not TIMP-1 expression by equivalent numbers of Trx-
1 and pcDNA transfectants, assayed in 10 fold concentrated 48 h
serum-free conditioned medium, by Western blot (Fig. 3E).
3.5. Trx-1 augments AP-1, SP-1 and NF-kB activity in EMSAs
AP-1, SP-1 and NF-jB site binding activity was assessed in nu-
clear extracts from pcDNA, Trx-1 and dnTrx-1 transfectants, by
EMSA. Comparative densitometric analysis of the ratio between
speciﬁc and non-speciﬁc binding complexes, using pcDNA trans-
fectants as a baseline, revealed that Trx-1 MDA-MB-231 transfec-
tants exhibited a 65% increase in AP-1, a 54% increase in SP-1
and a 90% increase in NF-jB site binding activity, whereas dn-
Trx transfectants exhibited a 55% decrease in AP-1, a 32% decrease
in SP-1 and a 22% decrease in NF-jB site binding activity (Fig. 4A).
Binding speciﬁcity was conﬁrmed by competition EMSA in which
cold-speciﬁc but not cold non-speciﬁc oligonucleotides competed
with labelled probe (data not displayed). The protein composition
of NF-jB complexes determined by supershift EMSA conﬁrmed the
presence of p50 in NF-jB complexes from pcDNA, Trx-1 and dn-
Trx-1 transfectants, and detected p65 exclusively in NF-jB com-
plexes from Trx-1 transfectants (Fig. 4B). Densitometric analysis
of Westerns revealed a 96% increase in p50 and 46% increase in
p65, relative to Mta1, in nuclear extracts from Trx-1 transfectants,
and a 40% decrease in p50 and 65% decrease in p65, relative to
Mta1, in dn-Trx-1 transfectants, when compared to pcDNA trans-
fectants (Fig. 4C).
3.6. Trx-1 regulates NF-jB recruitment to the endogenous MMP-9
promoter
ChIp assay detected p50 but not p65 at the endogenous MMP-9
promoter in pcDNA transfectants; p50 and p65 at the endogenous
MMP-9 promoter in Trx-1 transfectants but did not detect either
p50 or p65 at the endogenous MMP-9 promoter in dnTrx-1 trans-
fectants (Fig. 5A).
3.7. HDACs at the MMP-9 promoter mediate MMP-9 repression
ChIp assays also detected acetylated histone 3 but not HDAC-1,
HDAC-2 or Mta1 at the endogenous MMP-9 promoter in pcDNA
and Trx-1 transfectants, and detected HDAC-1, HDAC-2 and
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Fig. 3. (A) RT-PCR/Southern blots comparing the effects of actinomycin D (5 lg/ml) on MMP-9, TIMP-1 and GAPDH mRNA levels in stable pcDNA control and Trx-1
transfectants over 10 h. (B) Diagram outlining the MMP-9 promoter intact and mutated constructs plus histogram comparing percent differences in luciferase reporter gene
activity from intact; GTbox mutated (-670MMP-9GTmu); AP1 mutated (-670MMP-9AP-1mu), SP1 mutated (-670MMP-9SP1mu) and NFjB mutated (-670MMP-9NFjBmu)
reporter gene constructs in stable pcDNA, Trx-1 and dnTrx-1 transfectants. (C) Histogram demonstrating differences in NF-jB-luciferase reporter gene activity in pcDNA, Trx-
1 and dnTrx-1 transfectants, displayed as mean percent difference in activity (±S.E.), compared to pcDNA controls (arbitrary value, 100%), in three independent experiments
performed in duplicate. (D) Histogram comparing percent differences in luciferase reporter gene activity from -670MMP-9Luc reporter gene following 48 h transient
transfection of Trx-1 and pcDNA stable transfectants with either nothing (NT), dn-I-jBa or pmT2T control vector. Results are displayed as the mean percentage difference to
luciferase activity (±S.E.) from the intact promoter in non-treated pcDNA transfectant controls (arbitrary value, 100%), in three independent experiments performed in
duplicate (⁄signiﬁcant difference). (E) Western blots demonstrating differences in MMP-9 relative to TIMP-1 expression in 48 h serum-free conditioned medium from equal
numbers of stable Trx-1 and pcDNA transfectants transiently transfected with either pmT2T control or dn-I-jBa vector. The adjacent histogram shows the percent difference
in MMP-9 and TIMP-1 levels assessed by densitometry of the adjacent Westerns, using transient pmT2T-transfected pcDNA control (100%) as the baseline.
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Trx-1 transfectants (Fig. 5A). Densitometric analysis of Western
blots revealed similar levels of Mta1 in nuclear extracts frompcDNA, Trx-1 and dn-Trx-1 transfectants (Fig. 4C). The HDAC
inhibitor TSA (100 ng/ml for 48 h) restored MMP-9 expression
to dn-Trx-1 transfectants, without effecting the expression of
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either pcDNA or Trx-1 transfectants (Fig. 5B).
4. Discussion
We report a novel functional relationship between breast
cancer metastasis-associated genes Trx-1 and MMP-9 in a MDA-
MB-231 cell model of malignant p53 and ER-independent breast
cancer. This relationship is characterised by Trx-1 stimulation of
MMP-9 expression; de-regulation of the equilibrium between
MMP-9 and its tissue speciﬁc inhibitor TIMP-1; and stimulation
of MMP-9 involvement in a more invasive phenotype. We show
that Trx-1 stimulates MMP-9 expression at the transcriptional le-
vel through AP-1, SP-1 and NF-jB sites within the MMP-9 pro-moter, modiﬁes NF-jB DNA binding activity and recruitment to
the endogenous MMP-9 promoter, increasing NF-jB-mediated
MMP-9 transcription. Finally, we show that these Trx-1-mediated
effects are reversed by dominant negative inhibition of both Trx-
1 and NF-jB.
Our observations are the ﬁrst to report a functional relationship
between Trx-1 and MMP-9 in breast cancer cells and provide a po-
tential explanation for the association between the overexpression
of Trx-1 and MMP-9 in malignant breast cancer [1–15]. Increased
Trx-1 expression in breast tumours, modelled in this study, is likely
to reﬂect not only tumour-associated oncogenic activity but also
oxidative-stress within the tumour microenvironment, which
stimulates Trx-1 redox system expression in order to buffer oxida-
tive stress-associated toxicity [43]. The net effect of this, combined
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cues for survival within and escape from the stressful tumor micro-
environment, both of which characterise malignant progression.
Trx-1 exhibits both redox dependent and redox independent
biological activity [16,44]. Here, we report that Trx-1 stimulation
of MMP-9 expression and invasion is redox active site-dependent,
since both were inhibited by the dominant negative C32S/C35S-
mutated Trx-1 redox active site inhibitor [3,39]. This active site
cysteine to serine mutant acts as a dominant negative inhibitor
of Trx-1 by competing for Trx substrates including Trx reductase,
impairing their capacity to reduce oxidised Trx-1 [3,39].
MMP-9 involvement in malignant behaviour depends upon
alteration in equilibrium with its tissue speciﬁc inhibitor, TIMP-
1 [7]. MMP-9 involvement in Trx-1 stimulated invasion was con-
ﬁrmed using exogenous TIMP-1 and an anti-catalytic anti-MMP-9
antibody, both of which inhibited Trx-1 transfectant but not non-
MMP-9 expressing dnTrx-1 transfectant invasion. MMP-9
involvement in invasion was associated with increased MMP-9
but not TIMP-1 expression, producing an altered MMP-9/TIMP-1
equilibrium in favour of MMP-9. This adds to our previous report
that extracellular Trx-1 de-regulates the MMP-9/TIMP-1 equilib-
rium and stimulates human neuroblastoma cells invasion by
direct TIMP inhibition [19], and indicates that Trx-1 can de-
regulate the MMP-9/TIMP-1 equilibrium to stimulate invasion
at both the transcriptional (this study) and post translational[19] level. We do not exclude, however, that Trx-1 may also
inﬂuence other aspects of the invasion process, since it is chemo-
tactic and alters cellular adhesive interactions with extracellular
matrices [18,45].
Trx-1 stimulation of MMP-9 expression did not result from in-
creased mRNA stability but rather increased transcription. This
involved combined increased transcription through AP-1 (-79),
SP1 (-560) and NF-jB(-600) elements, conﬁrming reports that
these element function in MMP-9 transcription [27,28,32,34–36]
and that Trx-1 regulates AP-1, Sp1 and NF-jB transcription factor
activity [20–22]. Although Trx-1 increased both AP-1 and NF-jB
binding activity, we chose to study NF-jB in more detail as AP-1
involvement in MMP-9 transcription is NF-jB dependent [34].
Focussing on NF-jB, we observed that Trx-1 overexpression al-
tered NF-jB DNA binding activity, promoted formation of NF-jB
complexes containing p50 and p65 and their recruitment to the
endogenous MMP-9 promoter, resulting in increased NF-jB-medi-
ated MMP-9 transcription. NF-jB involvement in MMP-9 tran-
scription was conﬁrmed by dominant negative mutated I-jBa
inhibition of MMP-9 transcription [38]. Therefore, Trx-1 redox
activity promotes p50/p65 NF-jB heterodimer formation, function
and recruitment to the endogenous MMP-9 promoter, increasing
MMP-9 transcription. Furthermore, dn-I-jBa also inhibited the
invasion of both control and Trx-1 but not dnTrx-1 transfectants,
conﬁrming NF-jB involvement in invasion.
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MDA-MB-231 transfectants exhibited reduced invasion insensitive
to MMP-9 inhibitors and did not express MMP-9, helping to ex-
plain why transient dn-Trx transfection did not further reduce
invasion of this cell line. However, somewhat paradoxically, dn-
Trx-1 transfectants exhibited constitutive MMP-9 and NF-jB tran-
scriptional activity in reporter gene assay, constitutive NF-jB site
binding activity in EMSAs and the presence of p50 and p65 in nu-
clear extracts. Stable dn-Trx-1 transfectants did not, however, ex-
hibit p50 or p65 recruitment to the endogenous MMP-9
promoter, suggesting that inhibition of Trx-1 activity impedes
NF-jB access to the MMP-9 promoter, providing a potential expla-
nation for the abrogation of MMP-9 expression observed and high-
lighting the limit of reporter gene assays that fail to take into
account chromatin structure. This possibility was supported by
ChIp assay, which detected HDACs, involved in chromatin remod-
elling, in the absence of acetylated histone 3 and NF-jB at the
endogenous MMP-9 promoter in dn-Trx-1 transfectants, but de-
tected acetylated histone 3 and NF-jB but not HDACs at the
MMP-9 promoter in control and Trx-1 transfectants. A potential
role for HDACs in MMP-9 transcriptional repression was conﬁrmed
using the HDAC inhibitor Trichostatin A [46], which restored MMP-
9 expression to dn-Trx-1 transfectants, adding to a report that
HDACs mediate MMP-9 transcriptional repression [37] and identi-
fying Trx-1 as a potential regulator of this process. These data sug-
gest that increased Trx-1 activity stimulates NF-jB activity but
blocks HDAC recruitment to the MMP-9 promoter facilitating
MMP-9 expression, whereas reduced Trx-1 activity inhibits
MMP-9 expression by promoting HDAC recruitment to the endog-
enous MMP-9 promoter, impeding NF-jB access as a consequence
of histone de-acetylation. Although we did not assess the direct ef-
fects of Trx-1 and dnTrx-1 upon HDAC expression, our data indi-
cate that within the context of the MMP-9 promoter Trx-1
regulates NF-jB and HDAC recruitment oppositely, with NF-jB
recruitment a consequence of HDAC absence and vice versa.
Although, the mechanism through which Trx-1 regulates HDAC
involvement in MMP-9 expression remain to be fully elucidated,
the HDAC recruiter and MMP-9 transcriptional repressor Mta-1
[37] was also detected at the MMP-9 promoter in dn-Trx-1 but
not pcDNA nor Trx-1 transfectants, suggesting that Mta-1 may
mediate HDAC recruitment and MMP-9 transcriptional repression
in dnTrx transfectant. This interesting possibility is under current
investigation.
In conclusion, our data provide a functional transcriptional ba-
sis for the association between MMP-9 and Trx-1 overexpression in
breast cancer, characterise NF-jB as a critical determinant of this
effect and identify both Trx-1 and NF-jB as a pivotal potential
druggable therapeutic targets for reducing MMP-9 involvement
in malignant breast cancer.
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